Calopedos Ross J S, Bang Albert, Baade Peter, Yu Xue Q, Ruthven Stephen, Patel Manish I, Smith David P
Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia.
Gosford Hospital, Gosford, New South Wales, Australia.
Aust J Rural Health. 2019 Jun;27(3):216-223. doi: 10.1111/ajr.12504. Epub 2019 May 9.
Describes the variation in prostate cancer testing by the remoteness of residence and socio-economic status groups in Australia.
A national population-based descriptive study using Medicare data extracted by the Department of Health (formerly the Department of Health and Ageing).
Australia.
All men, with a Medicare-reimbursed prostate-specific antigen test conducted in Australia between 2002 and 2017, were included. We focused on "screening and case finding" tests (Medicare Benefits Schedule item number 66655) from 1 April 2005 to 31 December 2009, to describe testing differences in subgroups. Groups were categorised into State and Territory, socio-economic status and region of residence. A negative binomial regression model was fitted to measure the incidence rate ratios of those who had a screening prostate-specific antigen test by group.
Age-standardised testing rates and incidence rate ratios.
Between 2002 and 2017, 11 588 775 screening prostate-specific antigen tests were reimbursed by the Department of Human Services. During 2005-2009, 52% of all Australian men, aged 40 years and over, had a screening test. The incidence rate ratios differed by State and Territory. Men aged 40 years and over, living in very remote areas, were 43% less likely to have had a screening test than residents of major cities. Prostate-specific antigen testing rates fell in all age groups between 2007 and 2009 and 2017.
The prostate-specific antigen testing behaviour differs between community groups in Australia. Men were less likely to have had a screening prostate-specific antigen test the farther they lived from the major cities. This highlights the need for a more targeted approach to achieve an equitable and evidence-based prostate cancer care across all sectors of the community.
描述澳大利亚不同居住偏远程度和社会经济地位群体的前列腺癌检测差异。
一项基于全国人口的描述性研究，使用卫生部（前身为卫生与老龄部）提取的医疗保险数据。
澳大利亚。
纳入2002年至2017年在澳大利亚进行医疗保险报销的前列腺特异性抗原检测的所有男性。我们重点关注2005年4月1日至2009年12月31日的“筛查和病例发现”检测（医疗保险福利计划项目编号66655），以描述亚组间的检测差异。分组依据州和领地、社会经济地位以及居住地区。采用负二项回归模型来衡量各群体进行前列腺特异性抗原筛查检测者的发病率比。
年龄标准化检测率和发病率比。
2002年至2017年期间，人类服务部报销了11588775次前列腺特异性抗原筛查检测。在2005 - 2009年期间，40岁及以上的澳大利亚男性中有52%进行了筛查检测。发病率比因州和领地而异。居住在极偏远地区的40岁及以上男性进行筛查检测的可能性比大城市居民低43%。2007年至2009年以及2017年期间，所有年龄组的前列腺特异性抗原检测率均有所下降。
澳大利亚不同社区群体的前列腺特异性抗原检测行为存在差异。男性居住离大城市越远，进行前列腺特异性抗原筛查检测的可能性越小。这凸显了需要采取更具针对性的方法，以在社区各部门实现公平且基于证据的前列腺癌护理。
